We’re pleased to announce that the CODEX® platform has been named a Top 10 Innovation of 2019 by The Scientist.
Each year, an expert panel of judges identifies newly released products making the largest impact on life science research. The goal of the annual competition is to determine which products have the potential to revolutionize research and advance scientific knowledge. Products are evaluated based on their ability to facilitate research advances and address specific challenges within their fields.
The CODEX® platform enables spatially resolved, highly multiplexed biomarker analysis. The instrument integrates with existing fluorescence microscopes and uses iterative imaging cycles to visualize biomarkers without degrading tissue samples. By imaging three markers at a time, CODEX® avoids spectral overlap, an issue arising from too many fluorescent colors on a sample, making it difficult to distinguish between them.
Judges appreciated the simplicity of the CODEX® system, noting that it makes multiplexed antibody detection more accessible to researchers.
“We’re excited to have CODEX recognized as a Top 10 Innovation of 2019,” said Brian McKelligon, CEO of Akoya Biosciences. “Spatial context is essential for biomarker discovery, and CODEX is a simple, powerful tool that makes it easy for scientists to incorporate spatial analysis in their research.”
Click here to learn more about CODEX® or visit The Scientist’s website to view the full list of award winners
Related Posts
Neurology
Protected: Longitudinal Blood-Based Biomarker Monitoring in Multiple Sclerosis: Why Nf-L and GFAP Matter
There is no excerpt because this is a protected post.
Part 2 – Multimodal Diagnostics: Integrating tissue and blood biopsies
Realizing the promise of multimodal diagnostics raises important questions: How should we think about integrating these different sources of information? Where can multimodal approaches add the most value? And what…
Part 1 – Multimodal Diagnostics: Integrating tissue and blood biopsies
Disease is complex, dynamic, and heterogeneous, and no one biomarker modality can capture every dimension of that complexity. Liquid and tissue biomarkers answer different biological questions, each providing a distinct…
Cancer
Mapping the Tumor Immune Microenvironment: Spatial Biology Insights into Immunotherapy Response in NSCLC
Lung cancer is a formidable foe. Globally, it is the leading cause of cancer-related deaths in men and women, with non-small lung cancer (NSCLC) representing more than 80% of all…
Synaptic Dysfunction and Neuroinflammation: Complementary Pathways Driving Cognitive Decline
Accelerator Laboratory Services: The Biomarker Powerhouse
Proteomics in Transition: From Discovery to Diagnostic Utility
The promise of proteomics lies in its ability to illuminate disease biology at scale, transform translational research, and guide the development of precision diagnostics and targeted therapies. While genomic technologies…
Built for Translation: Why Simoa Stands Alone in Clinical-Grade Biomarker Measurement
Translating proteomic discovery into clinical action requires more than scale, it demands precision, reproducibility, and quantitative clarity. The Quanterix Simoa® digital immunoassay technology was purpose-built to meet the demands of…